Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment of early AD, binds with high affinity to soluble Aβ...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2024-05-01
Σειρά:	Alzheimer’s Research & Therapy
Θέματα:	Alzheimer’s disease Lecanemab Safety ARIA
Διαθέσιμο Online:	https://doi.org/10.1186/s13195-024-01441-8
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!